"Agile Medical" Secures Hundreds of Millions in Series B Funding to Accelerate Clinical Application of Laparoscopic Surgical Robots | Exclusive Report by 36Kr
36Kr learned that "Agile Medical" recently completed a Series B financing of hundreds of millions of RMB. The round was led by Mingxi Capital, with Yuanhe Holdings, Lichen Investment, and Nantong Investment Management participating as follow - on investors. Existing shareholders Qianji Capital and Yuanhe Origin continued to increase their investments. This round of financing will mainly be used for global commercial expansion, R & D and iteration of surgical robot products, and the upgrade of cutting - edge technology platforms.
In March 2025, AGIBOT®, the core product of Agile Medical, was approved for market launch. Currently, this product has been clinically applied in over a hundred complex surgical procedures in top - tier hospitals such as the Affiliated Drum Tower Hospital of Nanjing University Medical School, the First Affiliated Hospital of Zhengzhou University, and Suzhou Municipal Hospital. In clinical practice, it can meet the requirements of normalizing four - or five - consecutive surgical operations.
In clinical practice, in addition to stability, innovation based on real - world scenarios to enhance usability is also crucial. It is reported that the AGIBOT® laparoscopic surgical robot adopts an integrated hanging tray configuration and is equipped with a dual - guidance system of laser + camera visualization, reducing the average docking time to less than 3 minutes. Meanwhile, its patient surgical platform is equipped with a force - sensing module and a dual - motor drive, enabling medical staff to move the trolley with one hand and deploy it flexibly even in a crowded operating room.
"Guided by clinical needs" is an important principle in the development of medical devices, especially surgical robots. However, there are many difficulties in the integration of medicine and engineering in practice. During the product R & D process, Agile Medical attaches great importance to the needs of front - line clinical practice and implements them in the R & D process.
For example, during complex laparoscopic surgeries, doctors need to perform delicate operations in a narrow body cavity. To avoid damaging important blood vessels during the operation, the robot has improved the movement flexibility and control accuracy of the instrument tip. Additionally, to support cross - quadrant surgical operations, based on its four - arm configuration and 8 - degree - of - freedom surgical arms, the Agile robot provides doctors with an effective operating space of over 96 liters.
Moreover, as the number of clinical cases of this laparoscopic surgical robot increases, its intelligent platform can collect more front - line surgical data and feedback, which will be analyzed through artificial intelligence to support further iterative optimization of the product.
After entering the commercialization stage, cost control and supply - chain controllability of laparoscopic surgical robots have become one of the keys to their competition at home and abroad. It is reported that Agile Medical has chosen the path of full - stack self - research of core technologies. Currently, it has established a R & D and production base of over 10,000 square meters in Suzhou, "with the manufacturing and supply capacity of producing 100 system units and 20,000 sets of surgical instruments annually".
Next, Agile Medical will continue to conduct R & D in areas such as force feedback and strengthen its AI capabilities to enable surgical robots to have stronger perception and decision - making abilities and achieve intelligent upgrades. At the same time, it has also initiated the overseas certification process for its products and is in contact with potential clinical partners in multiple overseas markets to prepare for its overseas expansion.